Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus lapatinib or trastuzumab or both in HER2-positive primary breast cancer
2006-001839-21Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Chemotherapy + lapatinib, Chemotherapy + trastuzumab and Chemotherapy + lapatinib + trastuzumab (3 arms). Primary endpoint: Pathological complete response. Started Aug 2006; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-001839-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001839-21.